Of note, therapies that have shown consistently to improve HF survival (e.g. angiotensin-converting enzyme inhibitors, spironolactone, beta blockers, etc) were demonstrated to simultaneously improve endothelial function (Marti et al., 2012). This evidence concerns the gene ACE and hydrops fetalis.